Lineage Cell Therapeutics (NYSE: LCTX) is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs and is committed to becoming the preeminent allogeneic cell transplant company. In 2020, the Company reached significant clinical, manufacturing, and business milestones with all three of its clinical stage programs. Lineage’s strength lies in the combination of its cell therapy patent breadth, in-house manufacturing capabilities, and encouraging clinical evidence in three distinct disease areas, each with large unmet needs and billion-dollar commercial opportunities.
With its robust proprietary cell-based therapy platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.
The field of cell therapy is poised for explosive growth and Lineage’s objective is to be positioned for that growth by continuing to provide evidence that allogeneic, or “off-the-shelf” approaches can generate safety and efficacy data which leads to commercial and clinical advantages over alternate approaches.Lineage’s clinical programs include three allogeneic product candidates:
- OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world
- OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries
- VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer.